
Brainstorm Cell Therapeutics BCLI
Annual report 2025
added 03-31-2026
Brainstorm Cell Therapeutics ROCE Ratio 2011-2026 | BCLI
Annual ROCE Ratio Brainstorm Cell Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 163.63 | 596.85 | 7112.32 | -106.88 | -79.16 | 206.84 | -280.36 | -85.02 | -51.33 | -60.42 | -109.16 | -147.85 | -84.34 | -242.01 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7112.32 | -280.36 | 488.08 |
Quarterly ROCE Ratio Brainstorm Cell Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 172.35 | 205.84 | 311.19 | 279.81 | 1224.25 | 2108.43 | 2240.22 | 1426.74 | 1267.87 | 164.56 | -184.04 | -256.89 | -275.28 | -134.8 | -84.42 | -53.46 | -64.67 | -57.48 | -58.06 | -50.45 | -0.53 | 60.59 | 122.76 | 137.91 | 73.48 | -40.87 | -146.09 | -171.97 | -212.65 | -188.9 | -145.64 | -89.06 | -105.61 | -81.47 | -73.11 | -44.77 | -62.97 | -64.62 | -71.42 | -50.53 | -86.28 | -103.82 | -106.13 | -85.83 | -117.68 | -113.79 | -138.95 | -107.93 | -136.81 | -133.84 | -110.46 | -71.5 | -118.14 | -135.9 | -41.69 | 74.13 | -46.64 | 73.39 | 47.38 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2240.22 | -275.28 | 94.34 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
17.8 | $ 21.65 | 1.12 % | $ 1.01 B | ||
|
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | ||
|
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
31.5 | $ 22.3 | 1.55 % | $ 3.7 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | ||
|
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | ||
|
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
-116.14 | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-75.24 | - | -11.43 % | $ 502 K | ||
|
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - | ||
|
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M | ||
|
Applied Therapeutics
APLT
|
394.73 | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | ||
|
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | ||
|
Aravive
ARAV
|
-664.7 | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
123.77 | - | 17.91 % | $ 11.1 M | ||
|
BioNTech SE
BNTX
|
-4.81 | $ 102.06 | -3.22 % | $ 27.2 B | ||
|
Avenue Therapeutics
ATXI
|
-168.29 | - | -52.27 % | $ 4.45 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
211.07 | $ 4.1 | 0.49 % | $ 438 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 23.42 | 0.69 % | $ 2.98 B | ||
|
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M | ||
|
Autolus Therapeutics plc
AUTL
|
-151.88 | $ 1.42 | -1.39 % | $ 378 M | ||
|
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | ||
|
AstraZeneca PLC
AZN
|
11.12 | - | - | $ 96.9 B | ||
|
AVROBIO
AVRO
|
10.76 | - | 1083.1 % | $ 745 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 2.92 | -0.34 % | $ 4.81 M | ||
|
Esperion Therapeutics
ESPR
|
-19.96 | $ 1.91 | - | $ 397 M | ||
|
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
7.03 | - | 0.49 % | $ 251 B | ||
|
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | ||
|
bluebird bio
BLUE
|
-125.56 | - | - | $ 546 M | ||
|
ContraFect Corporation
CFRX
|
545.12 | - | -5.16 % | $ 5.39 M | ||
|
Cardiff Oncology
CRDF
|
-107.87 | $ 1.72 | - | $ 115 M | ||
|
BioXcel Therapeutics
BTAI
|
52.86 | $ 1.09 | 2.83 % | $ 13.3 M | ||
|
Cabaletta Bio
CABA
|
-153.72 | $ 2.91 | -1.36 % | $ 292 M | ||
|
Cara Therapeutics
CARA
|
-127.7 | - | -3.03 % | $ 260 M | ||
|
Allena Pharmaceuticals
ALNA
|
-252.54 | - | 3.16 % | $ 1.9 M | ||
|
CASI Pharmaceuticals
CASI
|
-49.51 | - | - | $ 35.4 M |